Mealey's (July 28, 2020, 3:08 PM EDT) -- WASHINGTON, D.C. — In a June 26 petition for certiorari in the U.S. Supreme Court, pharmaceutical firm Sanofi-Aventis Deutschland GMBH seeks review of two areas in patent law: the application or forfeiture of a change of law during a case's pendency and the proper flexibility standard when finding obviousness in an invention (Sanofi-Aventis Deutschland GMBH v. Mylan Pharmaceuticals Inc., No. 19-1451, U.S. Sup.)....